ClinicalTrials.gg
RecruitingNCT07677358Updated Aug 21, 2026

A Study to Learn How the Study Medicine Called Atirmociclib is Handled by the Body in People With Normal Liver Function and Different Levels of Liver Disease

A Phase 1 interventional study of Atirmociclib in Hepatic Impairment, Healthy, Hepatic Insufficiency and Healthy Adults, sponsored by Pfizer. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by Pfizer · Phase 1, Interventional, and Other

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 52 studies in Hepatic Insufficiency with a site in United States — 3 open to participants now, 4 under way, none of them phase 3. Hepatic Insufficiency · United States.

Planned enrollment
24th of 48
28 · median 28
Started
2026
with 2 others
Phase 1
42 of 52
3 open now
Registered
52nd of 52
by date
Lead sponsor
5 of 52
Pfizer

Among the 52 studies in Hepatic Insufficiency with a site in United States, this one is the 24th largest by planned enrollment of the 48 interventional ones that give a count, is one of 3 that started in 2026, is one of 42 in phase 1, and was the 52nd registered.

Hepatic Insufficiency

113 studies on the registry are indexed under Hepatic Insufficiency; 15 are open to participants now.

Browse Hepatic Insufficiency studies →

Open to participants now

3 of the 52 studies in Hepatic Insufficiency with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Hepatic Insufficiency studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Hepatic Insufficiency with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study to understand how the study medicine atirmociclib behaves in the body and how safe it is for people with different levels of liver health.

The study is seeking participants who are:

  • Aged 18 years or older
  • Have a BMI of 17.5 to 40 kg/m2, and body weight more than 50 kg.
  • Have normal liver function or have stable mild, moderate, or severe liver disease

Participants will receive study medicine by mouth. Blood samples will be collected to see how much of the medicine is in the body over time. This will help understand whether liver disease changes how the medicine is handled.

Participants will be in the study for about 9 weeks. Those with normal liver function will stay in the clinic for about 7 days. People with liver disease will stay for about 9 days. After leaving the clinic, people may be contacted for follow-up. This may be done by phone or through a clinic visit.

03

Conditions studied

  • Hepatic Impairment
  • Healthy, Hepatic Insufficiency
  • Healthy Adults

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • of 17.5-40 kg/m2; and a total body weight >50 kg (110 lb).
  • Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
  • Capable of giving signed .

Normal hepatic function group only:

- Overtly healthy as determined by medical evaluations including medical history, physical examination, laboratory tests, vital signs and standard 12-lead ECGs.

Hepatic impairment groups only:

- Stable hepatic impairment meeting the criteria for Class A, B, or C . Stable hepatic impairment is defined as no change in disease status within the last 28 days prior to the screening visit, as documented by the participant's recent medical history.

Exclusion criteria

Exclusion criteria including but not limited to:

  • Any condition or history of surgery possibly affecting drug absorption.
  • Use of prohibited prior or concomitant medications.

Normal hepatic function group only:

- Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).

Hepatic impairment groups only:

- A diagnosis of hepatic dysfunction secondary to any acute ongoing hepatocellular process that is documented by medical history, PE, liver , hepatic ultrasound, CT scan, or MRI.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
28 participants (estimated)

Study arms

  • Experimental
    Group 1: Normal Hepatic Function

    Atirmociclib administered as a single oral dose

    Drug: Atirmociclib

  • Experimental
    Group 4: Severe Hepatic Impairment

    Atirmociclib administered as a single oral dose

    Drug: Atirmociclib

  • Experimental
    Group 3: Moderate Hepatic Impairment

    Atirmociclib administered as a single oral dose

    Drug: Atirmociclib

  • Experimental
    Group 2: Mild Hepatic Impairment

    Atirmociclib administered as a single oral dose

    Drug: Atirmociclib

Interventions

  • atirmociclib administered as a single oral dose

    Also known as: PF-07220060

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) for atirmociclib in participants with normal hepatic function

    Maximum observed plasma concentration (Cmax) for atirmociclib following a single oral dose in participants with normal hepatic function

    Time frame: Pre-dose and at, 1, 2, 4, 6, 8, 12, and 24, 36, 48, 60, 72, 96, 120, 144 hours after a single oral dose

  2. Maximum Observed Plasma Concentration (Cmax) for atirmociclib in participants with hepatic impairment

    Maximum observed plasma concentration (Cmax) for atirmociclib following a single oral dose in participants with hepatic impairment

    Time frame: Pre-dose and at, 1, 2, 4, 6, 8, 12, and 24, 36, 48, 60, 72, 96, 120, 144, 168, 192 hours after a single oral dose

  3. Area under the curve from time zero to extrapolated infinite time [AUC (0 - ∞)] for atirmociclib in participants with normal hepatic function

    AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

    Time frame: Pre-dose and at, 1, 2, 4, 6, 8, 12, and 24, 36, 48, 60, 72, 96, 120, 144 hours after a single oral dose

  4. Area under the curve from time zero to extrapolated infinite time [AUC (0 - ∞)] for atirmociclib in participants with impaired hepatic function

    AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

    Time frame: Pre-dose and at, 1, 2, 4, 6, 8, 12, and 24, 36, 48, 60, 72, 96, 120, 144, 168, 192 hours after a single oral dose

Secondary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events

    Time frame: Time from baseline through and including follow-up contact occurring 28 to 35 calendar days after the last administration of atirmociclib

  2. Number of Participants With Normal Hepatic Function having Clinically Significant Clinical Laboratory Abnormalities

    Time frame: Baseline and Day 2, Day 7 after a single oral dose of atirmociclib

  3. Number of Participants With Impaired Hepatic Function having Clinically Significant Clinical Laboratory Abnormalities

    Time frame: Baseline and Day 2, Day 9 after a single oral dose of atirmociclib

  4. Number of Participants With Normal Hepatic Function having Clinically Significant Change From Baseline in Vital Signs

    Time frame: Predose and at 4, 144 hours after a single oral dose of atirmociclib

  5. Number of Participants With Impaired Hepatic function having Clinically Significant Change From Baseline in Vital Signs

    Time frame: Predose and at 4, 192 hours after a single oral dose of atirmociclib

  6. Number of Participants With Normal Hepatic Function having Clinically Significant Electrocardiogram (ECG) Abnormalities

    Time frame: Predose and at 4, 144 hours after a single oral dose of atirmociclib

  7. Number of Participants With Impaired Hepatic Function having Clinically Significant Electrocardiogram (ECG) Abnormalities

    Time frame: Predose and at 4, 192 hours after a single oral dose of atirmociclib

07

Study locations

3 of 3 sites recruiting
  • Floridian Clinical Research
    Miami Lakes, Florida 33016, United States
    Recruiting
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
    Recruiting
  • Genesis Clinical Research
    Tampa, Florida 33603, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Aug 2027, 13 months after the start.

Of 38 industry-sponsored phase 1 interventional studies under Hepatic Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 17. This study's planned 13 months is above that.

Counting every sponsor, half of 41 studies reached it within 8 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2026
First posted
Jun 30, 2026
StartActual
Jun 29, 2026
Primary completionEst.
Aug 14, 2027
CompletionEst.
Sep 10, 2027
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07677358
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 30, 2026
Start date
Jun 29, 2026
Primary completion
Aug 14, 2027 (estimated)
Completion
Sep 10, 2027 (estimated)
Last update
Aug 21, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atirmociclib

Start the discussion